Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inleusin
- Development stage
- Phase 2
- Lead developer
- 3SBio
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Intramuscular, Intralesional
01
Overview
Inleusin is a recombinant human interleukin-2 (rhIL-2) immunotherapy developed and marketed by 3SBio. Approved by the Chinese National Medical Products Administration (NMPA) in 1995 and launched in 1996, it was one of the first domestically produced biotechnology drugs in China. Inleusin functions as a cytokine that binds to the interleukin-2 receptor (IL-2R) complex on the surface of immune cells, such as T-lymphocytes and natural killer (NK) cells. This binding triggers signaling pathways that promote the proliferation, differentiation, and activation of these effector cells, thereby enhancing the host's anti-tumor immune response. It is primarily indicated for the treatment of renal cell carcinoma and malignant melanoma, and is also used in the management of malignant pleural and peritoneal effusions.
- Brand names
- Inleusin
- Other names
- Recombinant Human Interleukin-2rhIL-2rhIL2rhIL 2Yinlaixin
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)IL2RB (IL-2 receptor beta chain)IL2RG (Interleukin-2 receptor gamma subunit)
Beyond the preview
Go deeper on Inleusin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inleusin.